Meeting
2022 ASCO Gastrointestinal Cancers Symposium
A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma.
Authors
Choong-kun Lee
Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
Choong-kun Lee , Ho Kyoung Hwang , Hei-Cheul Jeung , Hongjae Chon , Hyung Soon Park , Min Hwan Kim , Mi-Suk Park , Chang Moo Kang , Hye Jin Choi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
KCT0004421 (Registration ongoing for clinicaltrials.gov)
DOI
10.1200/JCO.2022.40.4_suppl.TPS624
Abstract #
TPS624
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma.
First Author: Choong-kun Lee
Poster
2023 ASCO Annual Meeting
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.
First Author: Sherise C. Rogers
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study).
First Author: Sherise C. Rogers
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Results of a phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study).
First Author: Thomas J. George